These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 31102976)
1. Brain volumetric correlates of dysarthria in multiple sclerosis. Rusz J; Vaneckova M; Benova B; Tykalova T; Novotny M; Ruzickova H; Uher T; Andelova M; Novotna K; Friedova L; Motyl J; Kucerova K; Krasensky J; Horakova D Brain Lang; 2019 Jul; 194():58-64. PubMed ID: 31102976 [TBL] [Abstract][Full Text] [Related]
2. Characteristics of motor speech phenotypes in multiple sclerosis. Rusz J; Benova B; Ruzickova H; Novotny M; Tykalova T; Hlavnicka J; Uher T; Vaneckova M; Andelova M; Novotna K; Kadrnozkova L; Horakova D Mult Scler Relat Disord; 2018 Jan; 19():62-69. PubMed ID: 29149697 [TBL] [Abstract][Full Text] [Related]
3. Brain atrophy and physical disability in primary progressive multiple sclerosis: A volumetric study. Galego O; Gouveia A; Batista S; Moura C; Machado E Neuroradiol J; 2015 Jun; 28(3):354-8. PubMed ID: 26246109 [TBL] [Abstract][Full Text] [Related]
4. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095 [TBL] [Abstract][Full Text] [Related]
5. Hereditary diffuse leukoencephalopathy with spheroids - a volumetric and radiological comparison with multiple sclerosis patients and healthy controls. Granberg T; Hashim F; Andersen O; Sundal C; Karrenbauer VD Eur J Neurol; 2016 Apr; 23(4):817-22. PubMed ID: 26756564 [TBL] [Abstract][Full Text] [Related]
6. Whole brain and grey matter volume of Japanese patients with multiple sclerosis. Akaishi T; Nakashima I; Mugikura S; Aoki M; Fujihara K J Neuroimmunol; 2017 May; 306():68-75. PubMed ID: 28385190 [TBL] [Abstract][Full Text] [Related]
7. Adult brain volume in multiple sclerosis: The impact of paediatric onset. Fenu G; Lorefice L; Loi L; Sechi V; Contu F; Coghe G; Frau J; Spinicci G; Barracciu MA; Marrosu MG; Cocco E Mult Scler Relat Disord; 2018 Apr; 21():103-107. PubMed ID: 29544192 [TBL] [Abstract][Full Text] [Related]
8. Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines. Chu R; Kim G; Tauhid S; Khalid F; Healy BC; Bakshi R PLoS One; 2018; 13(11):e0206939. PubMed ID: 30408094 [TBL] [Abstract][Full Text] [Related]
10. The role of global and regional gray matter volume decrease in multiple sclerosis. Grothe M; Lotze M; Langner S; Dressel A J Neurol; 2016 Jun; 263(6):1137-45. PubMed ID: 27094570 [TBL] [Abstract][Full Text] [Related]
15. 'Timed up and go' and brain atrophy: a preliminary MRI study to assess functional mobility performance in multiple sclerosis. Lorefice L; Coghe G; Fenu G; Porta M; Pilloni G; Frau J; Corona F; Sechi V; Barracciu MA; Marrosu MG; Pau M; Cocco E J Neurol; 2017 Nov; 264(11):2201-2204. PubMed ID: 28894919 [TBL] [Abstract][Full Text] [Related]
16. Grey:white matter ratio at diagnosis and the risk of 10-year multiple sclerosis progression. Moccia M; Quarantelli M; Lanzillo R; Cocozza S; Carotenuto A; Carotenuto B; Alfano B; Prinster A; Triassi M; Nardone A; Palladino R; Brunetti A; Brescia Morra V Eur J Neurol; 2017 Jan; 24(1):195-204. PubMed ID: 27801535 [TBL] [Abstract][Full Text] [Related]
17. Subcortical grey matter structures in multiple sclerosis: what is their role in cognition? Cruz-Gómez ÁJ; Aguirre N; Sanchis-Segura C; Ávila C; Forn C Neuroreport; 2018 May; 29(7):547-552. PubMed ID: 29465624 [TBL] [Abstract][Full Text] [Related]
18. Morphometric correlates of dysarthric deficit in amyotrophic lateral sclerosis. De Marco M; Merico A; Berta G; Segato N; Citton V; Baglione A; Venneri A Amyotroph Lateral Scler Frontotemporal Degener; 2015; 16(7-8):464-72. PubMed ID: 26121168 [TBL] [Abstract][Full Text] [Related]
19. Grey matter atrophy is associated with disability increase in natalizumab-treated patients. Ciampi E; Pareto D; Sastre-Garriga J; Vidal-Jordana A; Tur C; Río J; Tintoré M; Auger C; Rovira A; Montalban X Mult Scler; 2017 Apr; 23(4):556-566. PubMed ID: 27354019 [TBL] [Abstract][Full Text] [Related]